Celgene in den Nachrichten
Entdeckung innovativer Medikamente
Tamtam hat 20 aktuelle Artikel über Celgene gefunden.
- ANTITRUST—D.N.J.: Revlimid buyers’ pay-for-delay antitrust claims survive drugmakers’ motion to dismiss
- Bristol-Myers, Natco And More Can't Ditch Cancer Drug MDL
- Celgene, Teva, others must face US antitrust claims over Revlimid, judge rules
- Celgene Fails to Fend Off Antitrust Claims in Pay-for-Delay Suit
- Celgene, Teva, others must face US antitrust claims over Revlimid, judge rules
- Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
- What Does Bristol Myers Squibb (BMY) Risk From The Revived $6.7 Billion Lawsuit?
- Bristol Myers Squibb Faces Revival of USD 6.7 Billion Celgene Shareholders' Lawsuit
- Appeals court revived a $6.7 billion lawsuit against Bristol Myers Squibb over delayed drug approvals
- US appeals court revives $6.7 billion lawsuit against Bristol Myers Squibb
- Appeals court revives $6.7B lawsuit against Bristol Myers Squibb
- Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row
- Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row
- Celgene Number of Employees 2026 | Employee Count & Headcount Data
- Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row
- Bristol Myers Squibb stock trades steady as oncology revenue and Celgene legacy shape valuation
- Scleroderma Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Bayer, Novartis, GSK, Boehringer Ingelheim, Celgene Corp., Johnson & Johnson
- Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
- FDA decision: Iberdomide by Celgene (in 2026)
- How Bristol Is Building On Its $74 Billion Celgene Buyout With New 'Molecular Glue'
Von Tamtam gesammelte Artikel, die sich auf das Unternehmen beziehen, die neuesten zuerst. Jeder verlinkt auf seine Quelle.
Sie verkaufen an Unternehmen wie Celgene?
Tamtam findet die Unternehmen, die zu Ihrem idealen Kunden passen, recherchiert jeden Account und sagt Ihnen, wen Sie wann kontaktieren sollten.
Ähnliche Unternehmen finden